• Formula E concluded its inaugural Madrid E-Prix at the Circuito del Jarama, where Hankook’s iON Race operated consistently across the championship’s longest circuit
• The race marked the first single-header event to feature PIT BOOST, adding a new strategic layer alongside a revised ATTACK MODE
• Hankook also engaged fans at the Hankook booth in the Fan Village, highlighting its iON EV tire technology

MADRID, March 23, 2026 /PRNewswire/ — Global leading tire company Hankook Tire & Technology (hereafter Hankook), the exclusive tire supplier to the ABB FIA Formula E World Championship, equipped all teams as Formula E staged the 2026 CUPRA Raval Madrid E-Prix at the historic Circuito del Jarama. The race unfolded as a strategically complex contest shaped by Pit Boost, revised Attack Mode, and the demands of the championship’s longest circuit.

Round 6 of Season 12 unfolded over 23 laps of the 3.934 km Jarama circuit, where fast-flowing corners and plenty of elevation changes placed a premium on energy management and strategic execution. The first single-header use of PIT BOOST, alongside a revised ATTACK MODE, added an additional strategic dimension for teams.

António Félix Da Costa led Jaguar TCS Racing to victory at the inaugural Madrid E-Prix, securing a 1–2 finish ahead of teammate Mitch Evans, while Pascal Wehrlein completed the podium for Porsche Formula E Team. Strategy and energy management played a key role across the 23-lap race.

Throughout the race, Hankook supplied all teams with its iON Race tire, which delivered stable grip and controlled thermal performance as track conditions evolved across the weekend. Jarama’s fast directional changes and sustained cornering loads demanded predictable warm-up characteristics and consistent traction over the full race distance. Despite limited historical race data at the venue, the tire’s balanced performance window enabled teams to commit to their PIT BOOST and ATTACK MODE strategies with confidence.

“The Madrid E-Prix offered a valuable opportunity to see how teams adapted their strategy on Formula E’s longest circuit,” said Manfred Sandbichler, Senior Director of Hankook Motorsport. “With PIT BOOST and a revised ATTACK MODE influencing race dynamics, tire consistency was an important factor as teams managed energy and race pace across the 23-lap distance. Insights from Jarama will contribute to our ongoing collaboration with the championship as the season continues.”

With Round 6 completed in Madrid, the ABB FIA Formula E World Championship now turns to Rounds 7 and 8 in Berlin, where teams will face a contrasting challenge on the championship’s established Tempelhof circuit.

Source

Source: ZHEJIANG AIXINER STOCKINGS CO.,LTD.

Source

• Treatment with ZEGFROVY^® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet
• WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-free, targeted therapy
• In addition to improvement in PFS, ZEGFROVY^® also showed superior results in all secondary endpoints, including cORR, DOR, DCR, compared to platinum-based chemo doublet
• ZEGFROVY^® was generally well tolerated with a safety profile consistent with previous studies  

SHANGHAI, March 21, 2026 /PRNewswire/ — Dizal (SSE:688192) today announced that its multinational Phase 3 WU-KONG28 study evaluating ZEGFROVY^® (sunvozertinib) monotherapy as first-line treatment in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint with positive topline results.

The findings suggest that ZEGFROVY monotherapy has the potential to become the first and only chemo free, oral agent to treat newly diagnosed NSCLC patients with EGFR exon20ins.

WU-KONG28 is a multinational, open-label, randomized confirmatory phase 3 study evaluating ZEGFROVY versus platinum-based chemotherapy as first-line treatment in advanced NSCLC patients with EGFR exon20ins. The study enrolled patients across 16 countries and regions in Asia, Europe, North America and South America. The primary endpoint is progression-free survival (PFS) assessed by blinded independent central review (BICR). Topline results demonstrated that ZEGFROVY significantly improved PFS compared to platinum-based doublet chemotherapy, with meaningful clinical benefit. Detailed data from the primary analysis will be submitted for presentation at an upcoming international scientific congress.

“Finding a drug targeting EGFR exon 20 insertion mutations is especially challenging due to their enormous heterogeneity. We have identified over 100 different subtypes of EGFR exon20ins clinically. Despite tremendous efforts, there is no success yet in finding an effective target drug that can spare patients from chemotherapies. WU-KONG28 study has the potential to change all that.” said Dr. Xiaolin Zhang, CEO of Dizal. “The success of this multinational pivotal study further validates ZEGFROVY’s potential as first-line therapy for patients with EGFR exon20ins NSCLC. We extend our sincere gratitude to the patients, their families, and the investigators worldwide for their dedication and contribution to this study. We look forward to sharing comprehensive data with the global scientific community.”

“The positive topline results from WU-KONG28 study represent an important advancement for treating patients with EGFR exon20ins NSCLC,” said Prof. Caicun Zhou, MD, PhD of Shanghai East Hospital and the principal investigator of the study. “ZEGFROVY is currently the only single-agent, small-molecule targeted therapy approved in both China and the United States for patients with EGFR exon 20 insertion NSCLC. In this Phase 3 trial, first-line treatment with ZEGFROVY significantly prolonged PFS compared to platinum-based doublet chemotherapy. These results suggest that ZEGFROVY may offer an effective and convenient treatment option for treatment-naïve patients with EGFR exon20ins NSCLC.”

ZEGFROVY was previously approved in both China and the U.S. for the treatment of relapsed or refractory NSCLC with EGFR exon20ins. In the first-line setting, ZEGFROVY has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration (FDA) and China Center for Drug Evaluation (CDE). Based on WU-KONG28 study results, Dizal plans to engage with regulatory authorities regarding potential new drug applications (NDAs).

About ZEGFROVY^®(sunvozertinib)

ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The approval in China is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1 Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication.

In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations, as well as HER2 exon20ins.

ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.

WU-KONG28, a multinational, randomized Phase 3 study conducted across 16 countries and regions evaluating ZEGFROVY as first-line treatment for patients with EGFR exon20ins NSCLC, met its primary endpoint.

Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies. Dizal has two approved: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

Contacts
Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com

Source